RYTM - RHYTHM PHARMACEUTICALS, INC.

QQQ $ 459.86 $ 0.43 (0.09 %)

DIA $ 407.95 $ -1.96 (-0.48 %)

SPY $ 548.56 $ -1.34 (-0.24 %)

TLT $ 99.56 $ 0.56 (0.57 %)

GLD $ 232.35 $ 1.92 (0.83 %)

Previous Close

$ 48.27

Open

$ 46.72

Bid

$ 47.92 x 208

Ask

-- x --

Day's Range

$ 46.71 - $ 48.25

52 Week Range

$ 20.97 - $ 53.92

Volume

261,029

Average Volume

Market Cap

2.95B

Beta (5Y Monthly)

$ 1.07

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-06-2024	06-30-2024	10-Q
2	05-07-2024	03-31-2024	10-Q
3	02-29-2024	12-31-2023	10-K
4	11-08-2023	09-30-2023	10-Q
5	08-01-2023	06-30-2023	10-Q
6	05-02-2023	03-31-2023	10-Q
7	03-01-2023	12-31-2022	10-K
8	11-08-2022	09-30-2022	10-Q
9	08-03-2022	06-30-2022	10-Q
10	05-03-2022	03-31-2022	10-Q
11	03-01-2022	12-31-2021	10-K
12	11-02-2021	09-30-2021	10-Q
13	08-03-2021	06-30-2021	10-Q
14	05-03-2021	03-31-2021	10-Q
15	03-01-2021	12-31-2020	10-K
16	11-02-2020	09-30-2020	10-Q
17	08-03-2020	06-30-2020	10-Q
18	05-04-2020	03-31-2020	10-Q
19	03-02-2020	12-31-2019	10-K
20	11-01-2019	09-30-2019	10-Q
21	07-29-2019	06-30-2019	10-Q
22	05-03-2019	03-31-2019	10-Q
23	03-08-2019	12-31-2018	10-K
24	11-09-2018	09-30-2018	10-Q
25	08-08-2018	06-30-2018	10-Q
26	05-14-2018	03-31-2018	10-Q
27	03-12-2018	12-31-2017	10-K
28	11-14-2017	09-30-2017	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Rhythm Pharmaceuticals Announces FDA Accep...
08/26/2024 12:04:58

-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency -- -- FDA sets PDUFA goa...

Needham Reiterates Buy on Rhythm Pharmaceu...
08/07/2024 10:02:11

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $55 price target.

Rhythm Pharmaceuticals Says Cash On-hand E...
08/06/2024 11:19:59

For the year ending December 31, 2024, Rhythm anticipates approximately $250 million to $270 million in Non-GAAP Operating Expe...

Rhythm Pharmaceuticals Q2 2024 GAAP EPS $(...
08/06/2024 11:01:50

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate o...

Rhythm Pharmaceuticals Announces European ...
07/31/2024 13:11:08

A Glimpse Into The Expert Outlook On Rhyth...
07/25/2024 12:01:14

Needham Maintains Buy on Rhythm Pharmaceut...
07/25/2024 11:00:34

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $...

Rhythm Pharmaceuticals First Patients Dose...
07/23/2024 12:14:47

-- LB54640 has shown targeted effect on MC4R without hyperpigmentation -- BOSTON, July 23, 2024 (GLOBE NEWSWIRE) -- Rhythm Phar...

Rhythm Says European Medicines Agency's CH...
06/28/2024 12:02:51

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion ...

Rhythm Pharmaceuticals Grants Inducement E...
06/11/2024 20:02:03

Including Options For 9,230 Shares And RSUs For 46,850 Shares

Rhythm Pharmaceuticals Presents First Pati...
06/03/2024 20:04:43

- Participants from the completed Phase 2 hypothalamic obesity trial reported positive changes in sleep, energy levels during s...

Rhythm Pharmaceuticals Announced That The ...
05/22/2024 08:02:12

Canaccord Genuity Maintains Buy on Rhythm ...
05/08/2024 16:55:55

Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target...

B of A Securities Downgrades Rhythm Pharma...
05/08/2024 10:17:30

B of A Securities analyst Tazeen Ahmad downgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) from Buy to Neutral and lowers the pr...

Needham Maintains Buy on Rhythm Pharmaceut...
05/07/2024 18:11:57

Needham analyst Joseph Stringer maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $...

Rhythm Pharmaceuticals Q1 2024 GAAP EPS $(...
05/07/2024 11:02:02

Rhythm Pharmaceuticals Presents Data From ...
05/06/2024 12:15:08

-- Oral presentation showcased previously disclosed data that demonstrate setmelanotide achieved 3.04 mean reduction in BMI-Z s...

Rhythm Pharmaceuticals Announces Publicati...
04/29/2024 22:49:41

- Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks...

Analyst Expectations For Rhythm Pharmaceut...
04/26/2024 13:01:18

Needham Reiterates Buy on Rhythm Pharmaceu...
04/26/2024 10:39:34

Needham analyst Joseph Stringer reiterates Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and maintains $50 price target.